Beam Therapeutics Inc. (BEAM)

Market Cap	1.99B
Revenue (ttm)	349.64M
Net Income (ttm)	-143.59M
Shares Out	79.59M
EPS (ttm)	-1.75
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,160,244
Open	23.60
Previous Close	23.58
Day's Range	23.18 - 25.43
52-Week Range	20.84 - 49.50
Beta	1.86
Analysts	Buy
Price Target	45.90 (+83.23%)
Earnings Date	Nov 5, 2024

About BEAM

Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301,...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Feb 6, 2020
• Employees: 436
• Stock Exchange: NASDAQ
• Ticker Symbol: BEAM
• Website: https://beamtx.com

Financial Performance

In 2023, Beam Therapeutics's revenue was $377.71 million, an increase of 520.01% compared to the previous year's $60.92 million. Losses were -$132.53 million, -54.16% less than in 2022.

Analyst Forecast

According to 11 analysts, the average rating for BEAM stock is "Buy." The 12-month stock price forecast is $45.9, which is an increase of 83.23% from the latest price.

Price Target

$45.9

(83.23% upside)

Analyst Consensus: Buy